TTrialPathMatch Me to Trials
← Back to trials
RecruitingPulmonary HypertensionInterstitial Lung Disease (ILD)

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Eligible age

18+ yrs

Accepts

All genders

Locations

26 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Sponsor: Tempus AI

You may qualify if…

  • 18 years or older at the time of consent
  • A known diagnosis of interstitial lung disease
  • Diffusing capacity for carbon monoxide (DLCO) \<30% predicted, collected within 6 months prior to consent
  • Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required

You may not qualify if…

  • A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
  • A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
  • LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
  • Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
  • A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)
  • Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
  • There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)
  • There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix

Colorado

Denver

Florida

Orlando

Illinois

Chicago

Indiana

Indianapolis

Kentucky

Lexington

Louisiana

Bossier City · Shreveport

Michigan

Ann Arbor

Minnesota

Minneapolis

Source: ClinicalTrials.gov · NCT06911632 · last updated 2026-08-04

Multi-site Study of the Clinical Impact of an AI-assisted Approach to · TrialPath